Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MCK 
McKesson Corporation (MCK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: MCK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
17 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $788.57
1 Year Target Price $788.57
| 10 | Strong Buy |
| 3 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 43.17% | Avg. Invested days 75 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 86.25B USD | Price to earnings Ratio 27.78 | 1Y Target Price 788.57 |
Price to earnings Ratio 27.78 | 1Y Target Price 788.57 | ||
Volume (30-day avg) 17 | Beta 0.51 | 52 Weeks Range 462.37 - 737.02 | Updated Date 09/17/2025 |
52 Weeks Range 462.37 - 737.02 | Updated Date 09/17/2025 | ||
Dividends yield (FY) 0.40% | Basic EPS (TTM) 24.96 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.84% | Operating Margin (TTM) 1.29% |
Management Effectiveness
Return on Assets (TTM) 4.18% | Return on Equity (TTM) - |
Valuation
Trailing PE 27.78 | Forward PE 18.48 | Enterprise Value 93769357325 | Price to Sales(TTM) 0.23 |
Enterprise Value 93769357325 | Price to Sales(TTM) 0.23 | ||
Enterprise Value to Revenue 0.25 | Enterprise Value to EBITDA 18.07 | Shares Outstanding 124384000 | Shares Floating 124213986 |
Shares Outstanding 124384000 | Shares Floating 124213986 | ||
Percent Insiders 0.03 | Percent Institutions 90.66 |
Upturn AI SWOT
McKesson Corporation
Company Overview
History and Background
McKesson Corporation was founded in 1833. Initially a drug store, it has evolved into a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology, and specialty care.
Core Business Areas
- U.S. Pharmaceutical: Distributes branded, generic, specialty, and over-the-counter pharmaceutical products to retail pharmacies, institutional healthcare providers, and other channels.
- Prescription Technology Solutions: Provides software, services, and data solutions that connect pharmacies, payers, and providers to improve medication access and adherence.
- Medical-Surgical Solutions: Offers medical supplies, equipment, and logistics services to healthcare providers across the continuum of care.
- International: Operates in Europe and Canada, providing pharmaceutical distribution and related services.
Leadership and Structure
The CEO of McKesson Corporation is Brian Tyler. The organizational structure is a hierarchical model, with various business segments reporting to executive leadership.
Top Products and Market Share
Key Offerings
- Pharmaceutical Distribution: McKesson is a major distributor of pharmaceuticals to retail and institutional healthcare providers. Market share is significant, estimated around 25% of the North American market. Competitors include Cardinal Health and AmerisourceBergen.
- Onmark: McKesson's oncology care management solutions, offer comprehensive cancer care, clinical services, and population health management. Competitors include CVS Health, Optum and Ascension.
- Medical Supplies and Equipment: Distribution of various medical supplies and equipment. Competitors include Owens & Minor and Medline Industries.
Market Dynamics
Industry Overview
The pharmaceutical distribution industry is characterized by high consolidation, stringent regulations, and increasing demand for specialty drugs and integrated healthcare solutions.
Positioning
McKesson is positioned as one of the 'Big Three' pharmaceutical distributors, offering scale, comprehensive services, and a strong network. Its competitive advantages include its established relationships with manufacturers and providers.
Total Addressable Market (TAM)
The global pharmaceutical distribution market is estimated to be worth over $1 trillion. McKesson's is positioned to capture a substantial portion through its established distribution network.
Upturn SWOT Analysis
Strengths
- Extensive distribution network
- Strong relationships with pharmaceutical manufacturers
- Diversified business segments
- Advanced technology solutions
Weaknesses
- Exposure to generic pricing pressures
- Dependence on key suppliers
- Legal and regulatory risks
- High debt levels
Opportunities
- Growth in specialty pharmaceuticals
- Expansion into emerging markets
- Increased demand for integrated healthcare solutions
- Strategic acquisitions
Threats
- Increased competition
- Changes in healthcare regulations
- Economic downturns
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- CAH
- ABC
- AMZN
Competitive Landscape
McKesson is well-positioned due to its scale and comprehensive services. Competitors like Cardinal Health and AmerisourceBergen also have strong market presence. New competition comes from the technology sector like Amazon.
Major Acquisitions
CoverMyMeds
- Year: 2017
- Acquisition Price (USD millions): 1100
- Strategic Rationale: Enhanced prescription technology solutions and patient access.
Growth Trajectory and Initiatives
Historical Growth: McKesson's growth has been driven by organic expansion, strategic acquisitions, and increased demand for healthcare services.
Future Projections: Future growth is projected to be driven by growth in specialty pharmaceuticals, technology solutions and expansion into emerging markets. Analyst estimates are based on market conditions.
Recent Initiatives: Recent initiatives include investments in technology, expansion of specialty pharmacy services, and strategic acquisitions to strengthen its market position.
Summary
McKesson Corporation is a major player in the healthcare distribution and technology sector, leveraging its extensive network and diversified offerings. While the company faces challenges such as pricing pressure and regulatory risks, it is well-positioned to capitalize on growth opportunities in specialty pharmaceuticals and integrated healthcare solutions. Strategic acquisitions and investments in technology further support McKesson's growth trajectory. Potential threats to consider include increased competition and economic uncertainties.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Market Analysis Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions can change rapidly, and actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About McKesson Corporation
Exchange NYSE | Headquaters Irving, TX, United States | ||
IPO Launch date 1994-11-15 | CEO & Director Mr. Brian S. Tyler Ph.D. | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 43000 | Website https://www.mckesson.com |
Full time employees 43000 | Website https://www.mckesson.com | ||
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners to address challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver solutions to help people get the medicine needed to live healthier lives; and provides medication access and affordability, prescription decision support, prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services, as well as electronic prior authorization services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, biomedical maintenance, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, post-acute care facilities, hospital reference labs, and home health care agencies. The International segment delivers deliver medicines, supplies, and information technology solutions to retail pharmacies, hospitals, long-term care centers, clinics and institutions; and provides logistics and distribution services for manufacturers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.